Get started
Author

David Boyer

Observed names: David S Boyer, David S. Boyer
ORCID: 0000-0001-9219-1614
Observed ORCID: 0000-0001-9219-1614
OpenAlex ID: A5127860248
Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension
2026 · Dilsher Dhoot, Sunir Garg, et al. · Clinical ophthalmology · 3
PDF
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study
2026 · Sunil S Patel, David S Boyer, et al. · BMJ Open Ophthalmology · 2
PDF
Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration
2026 · David S. Boyer, Leonide Saad, et al. · Ophthalmology Retina · 1
Masquerading Disease of Macular Telangiectasia Type 2
2026 · Laurenz Pauleikhoff, Peter Charbel Issa, et al. · Ophthalmology Retina
Safety and Biological Activity of Intravitreal OGX110, a CXCR3 Agonist, in Persistent Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study
2026 · Alan Wells, David Boyer, et al. · medRxiv
PDF
Remote Physiologic Monitoring and Principal Care Management for Chronic Retinal Diseases: Results from over 80,000 Encounters
2026 · Sonia Dhoot, David Boyer, et al. · medRxiv
PDF
Oral Apx3330 Reduces The Drss Worsening After 24-Weeks Of Daily Treatment: Efficacy And Safety Results Of The Zeta-1 Phase 2 Trial In Diabetic Retinopathy
2023 · Mina Sooch, Louis Haddad, et al. · ESCRS Abstracts
Works count: 9
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type